Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase I, 2-Part, Open-label, Multiple Oral Dose Study of the Safety, Tolerability and Pharmacokinetics of up to Two Formulations of SMT C1100 in Healthy Adult Male Subjects and a Selected Formulation of SMT C1100 in Paediatric Subjects with Duchenne Muscular Dystrophy (DMD).

    Summary
    EudraCT number
    2015-001967-38
    Trial protocol
    GB  
    Global end of trial date
    28 Jun 2016

    Results information
    Results version number
    v2(current)
    This version publication date
    10 Mar 2017
    First version publication date
    07 Jan 2017
    Other versions
    v1
    Version creation reason
    • New data added to full data set
    The adverse events data split by dose, and additional information is added..

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    SMTC11004
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Summit (Oxford) Limited
    Sponsor organisation address
    85b Park Drive, Milton Park, Abingdon , United Kingdom, OX14 4RY
    Public contact
    Clinical Operations, Summit (Oxford) Limited, 0044 01235 443977, DMDphase1studies@summitplc.com
    Scientific contact
    Clinical Operations, Summit (Oxford) Limited, 0044 01235 443977, DMDphase1studies@summitplc.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    03 Dec 2016
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    28 Jun 2016
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Jun 2016
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Primary Objectives: Part A (Adult Subjects) To determine the multiple dose pharmacokinetics (PK) of SMT C1100, and its dihydrodiol metabolites (DHD I and DHD III), at 2 dose levels following oral administration with up to 2 different formulations of SMT C1100 in healthy adult male subjects. Part B (Paediatric Subjects) To determine the multiple dose PK of SMT C1100, and its dihydrodiol metabolites (DHD I and DHD III), following oral administration of up to 3 ascending dose regimens of the formulation of SMT C1100 selected from Part A in Duchenne Muscular Dystrophy (DMD) paediatric subjects.
    Protection of trial subjects
    Prior to enrolment subjects received a full explanation of the nature and purpose of the study, the safety of the drug under investigation, and discussion of any potential therapeutic benefit, and that they were free to withdraw from the study at any time without prejudice. An informed consent form approved by the IEC was signed by the subject and legal representative and the Investigator before any study-related procedures were performed. The Investigator provided copies of the signed informed consent to the subject or legal representative, and the original was retained by the Investigator.
    Background therapy
    Part A: Healthy Adult subjects were not to have prescribed medication within 14 days prior to the first dose administration until completion of the follow-up visit, and non-prescribed medication within 7 days prior to the first dose administration until completion of the follow-up visit. Use of paracetamol was permitted as clinically indicated. Part B: Paediatric DMD subjects were permitted systemic corticosteroids, angiotensin converting enzyme inhibitors, angiotensin-receptor blockers, beta blockers, bisphosphonates, vitamin D and calcium supplements. Use of inhibitors, inducers and substrates of CYP2B6, CYP1A1 and CYP1A2 was prohibited during the study and for at least 5 half-lives prior to the start of dose administration. In the interests of subject safety and acceptable standards of medical care the Investigator was permitted to prescribe treatment(s) at his/her discretion for both the parts (A and B).
    Evidence for comparator
    Not applicable; no comparators were used.
    Actual start date of recruitment
    02 Sep 2015
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 24
    Worldwide total number of subjects
    24
    EEA total number of subjects
    24
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    8
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    16
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The first informed consent was given on 2nd September 2015, and the date of last patient last visit was 28th June 2016. The final post-study observation was made on 05 July 2016.

    Pre-assignment
    Screening details
    Part A: Healthy Adult Subject Screening was performed within 28 days prior to initial dosing. Part B: Paediatric DMD subjects Screening was performed within 14 days prior to initial dosing.

    Pre-assignment period milestones
    Number of subjects started
    44 [1]
    Number of subjects completed
    24

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    Failed screening criteria: 18
    Reason: Number of subjects
    Withdrawal of consent: 2
    Notes
    [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: The number of subjects enrolled at the beginning of the pre-assignment period were 44; of these 18 failed screening criteria and 2 subjects withdrew consent.
    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Part A - Cohort 1 SMT C1100 oral suspension (F5)
    Arm description
    SMT C1100 suspension drug product (also referred to as Formulation 5 [F5]) was supplied as a suspension for oral administration at a dosage strength of 100 mg/g of SMT C1100. On Days 1 to 3 subjects received oral doses of SMT C1100 suspension at 3 g SMT C1100 bid followed by 6 g SMT C1100 bid on Days 4 and 5. On Days 1 to 5 doses were administered immediately after a meal, except the morning dose on Day 5, which was administered after an overnight fast.
    Arm type
    Experimental

    Investigational medicinal product name
    SMT C1100
    Investigational medicinal product code
    SMT C1100
    Other name
    Ezutromid
    Pharmaceutical forms
    Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    SMT C1100 suspension drug product was supplied as a suspension for oral administration at a dosage strength of 100 mg/g of SMT C1100. The suspension was filled into glass bottles. Each dose of SMT C1100 was closely followed by consumption of full fat (whole) milk on all days; subjects consumed 100 ml of whole milk after taking their SMT C1100 dose.

    Arm title
    Part A Cohort 2 SMT C1100 powder for oral suspension (F6)
    Arm description
    SMT C1100 powder for oral suspension (also referred to as Formulation 6 [F6]) was presented as a powder for reconstitution at a dosage strength of 250 mg/g of SMT C1100. The powder was presented in HDPE bottles and full fat (whole) milk was used as the reconstitution vehicle. On Days 1 (first day of dosing) to 3 subjects received oral doses of SMT C1100 powder for oral suspension at 2 g bid followed by 4 g bid on Days 4 and 5. On Days 1 to 5 doses were administered immediately after a meal, except the morning dose on Day 5, which was administered after an overnight fast.
    Arm type
    Experimental

    Investigational medicinal product name
    SMT C1100
    Investigational medicinal product code
    SMT C1100
    Other name
    Ezutromid
    Pharmaceutical forms
    Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    SMT C1100 powder for oral suspension (F6) was presented as a powder for reconstitution at a dosage strength of 250 mg/g of SMT C1100. The powder was presented in HDPE bottles and full fat (whole) milk was used as the reconstitution vehicle. Each dose of SMT C1100 was closely followed by consumption of full fat (whole) milk on all days; subjects consumed 100 ml of whole milk after taking their SMT C1100 dose.

    Arm title
    Part B SMT C1100 powder for oral suspension (F6)
    Arm description
    Subjects received SMT C1100 powder for oral suspension (F6) administered bid for 7 days in Treatment Period 1 (0.25 g bid), Treatment Period 2 (0.5 g bid) and Treatment Period 3 (1.0 g bid).
    Arm type
    Experimental

    Investigational medicinal product name
    SMT C1100
    Investigational medicinal product code
    SMT C1100
    Other name
    Ezutromid
    Pharmaceutical forms
    Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Each bottle of SMT C1100 powder for oral suspension was reconstituted in full fat (whole) milk for oral administration. Subjects received SMT C1100 powder for oral suspension 10 to 12-hourly, immediately following their breakfast and evening meal, closely followed by an additional 100 ml of full fat (whole) milk.

    Number of subjects in period 1
    Part A - Cohort 1 SMT C1100 oral suspension (F5) Part A Cohort 2 SMT C1100 powder for oral suspension (F6) Part B SMT C1100 powder for oral suspension (F6)
    Started
    8
    8
    8
    Completed
    8
    7
    5
    Not completed
    0
    1
    3
         Adverse event, non-fatal
    -
    1
    2
         Protocol deviation
    -
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial (overall period)
    Reporting group description
    -

    Reporting group values
    Overall trial (overall period) Total
    Number of subjects
    24 24
    Age categorical
    xx
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    8 8
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    16 16
        From 65-84 years
    0 0
        85 years and over
    0 0
        Not recorded
    0 0
    Gender categorical
    Units: Subjects
        Female
    0 0
        Male
    24 24
        Not recorded
    0 0
    Subject analysis sets

    Subject analysis set title
    Part A - Cohort 1, SMT C1100 , Day 1 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100 , Day 1 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 3 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 3 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 4 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 4 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 5 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 5 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 1 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 1 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F6 (3g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 3 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 3 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 4 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 4 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 5 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 5 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 1 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 1 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 3 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 3 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 4 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 4 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 5 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 5 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 PM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 1 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 1 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 3 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 3 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 4 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 4 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 5 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 5 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 1 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 1 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 3 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 3 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 4 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 4 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 5 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 5 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 1 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 1 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 3 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 3 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 4 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 4 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 5 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 5 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 PM.

    Subject analysis set title
    Part B - Treatment 1, SMT C1100, Day 1 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 1, SMT C1100, Day 1 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 2, SMT C1100, Day 1 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 2, SMT C1100, Day 1 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 3, SMT C1100, Day 1 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 3, SMT C1100, Day 1 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 1, SMT C1100, Day 7 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 1, SMT C1100, Day 7 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 2, SMT C1100, Day 7 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 2, SMT C1100, Day 7 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 3, SMT C1100, Day 7 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 3, SMT C1100, Day 7 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 1, DHD I, Day 1 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 1, DHD I, Day 1 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 2, DHD I, Day 1 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 2, DHD I, Day 1 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 3, DHD I, Day 1 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 3, DHD I, Day 1 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 1, DHD I, Day 7 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 1, DHD I, Day 7 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 2, DHD I, Day 7 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 2, DHD I, Day 7 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 3, DHD I, Day 7 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 3, DHD I, Day 7 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 1, DHD III, Day 1 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 1, DHD III, Day 1 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 2, DHD III, Day 1 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 2, DHD III, Day 1 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 3, DHD III, Day 1 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 3, DHD III, Day 1 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 1, DHD III, Day 7 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 1, DHD III, Day 7 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 2, DHD III, Day 7 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 2, DHD III, Day 7 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 3, DHD III, Day 7 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 3, DHD III, Day 7 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 PM.

    Subject analysis sets values
    Part A - Cohort 1, SMT C1100 , Day 1 (3g) AM Part A - Cohort 1, SMT C1100 , Day 1 (3g) PM Part A - Cohort 1, SMT C1100, Day 3 (3g) AM Part A - Cohort 1, SMT C1100, Day 3 (3g) PM Part A - Cohort 1, SMT C1100, Day 4 (6g) AM Part A - Cohort 1, SMT C1100, Day 4 (6g) PM Part A - Cohort 1, SMT C1100, Day 5 (6g) AM Part A - Cohort 1, SMT C1100, Day 5 (6g) PM Part A - Cohort 1, DHD I, Day 1 (3g) AM Part A - Cohort 1, DHD I, Day 1 (3g) PM Part A - Cohort 1, DHD I, Day 3 (3g) AM Part A - Cohort 1, DHD I, Day 3 (3g) PM Part A - Cohort 1, DHD I, Day 4 (6g) AM Part A - Cohort 1, DHD I, Day 4 (6g) PM Part A - Cohort 1, DHD I, Day 5 (6g) AM Part A - Cohort 1, DHD I, Day 5 (6g) PM Part A - Cohort 1, DHD III, Day 1 (3g) AM Part A - Cohort 1, DHD III, Day 1 (3g) PM Part A - Cohort 1, DHD III, Day 3 (3g) AM Part A - Cohort 1, DHD III, Day 3 (3g) PM Part A - Cohort 1, DHD III, Day 4 (6g) AM Part A - Cohort 1, DHD III, Day 4 (6g) PM Part A - Cohort 1, DHD III, Day 5 (6g) AM Part A - Cohort 1, DHD III, Day 5 (6g) PM Part A - Cohort 2, SMT C1100, Day 1 (2g) AM Part A - Cohort 2, SMT C1100, Day 1 (2g) PM Part A - Cohort 2, SMT C1100, Day 3 (2g) AM Part A - Cohort 2, SMT C1100, Day 3 (2g) PM Part A - Cohort 2, SMT C1100, Day 4 (4g) AM Part A - Cohort 2, SMT C1100, Day 4 (4g) PM Part A - Cohort 2, SMT C1100, Day 5 (4g) AM Part A - Cohort 2, SMT C1100, Day 5 (4g) PM Part A - Cohort 2, DHD I, Day 1 (2g) AM Part A - Cohort 2, DHD I, Day 1 (2g) PM Part A - Cohort 2, DHD I, Day 3 (2g) AM Part A - Cohort 2, DHD I, Day 3 (2g) PM Part A - Cohort 2, DHD I, Day 4 (4g) AM Part A - Cohort 2, DHD I, Day 4 (4g) PM Part A - Cohort 2, DHD I, Day 5 (4g) AM Part A - Cohort 2, DHD I, Day 5 (4g) PM Part A - Cohort 2, DHD III, Day 1 (2g) AM Part A - Cohort 2, DHD III, Day 1 (2g) PM Part A - Cohort 2, DHD III, Day 3 (2g) AM Part A - Cohort 2, DHD III, Day 3 (2g) PM Part A - Cohort 2, DHD III, Day 4 (4g) AM Part A - Cohort 2, DHD III, Day 4 (4g) PM Part A - Cohort 2, DHD III, Day 5 (4g) AM Part A - Cohort 2, DHD III, Day 5 (4g) PM Part B - Treatment 1, SMT C1100, Day 1 (0.25g) AM Part B - Treatment 1, SMT C1100, Day 1 (0.25g) PM Part B - Treatment 2, SMT C1100, Day 1 (0.5g) AM Part B - Treatment 2, SMT C1100, Day 1 (0.5g) PM Part B - Treatment 3, SMT C1100, Day 1 (1.0g) AM Part B - Treatment 3, SMT C1100, Day 1 (1.0g) PM Part B - Treatment 1, SMT C1100, Day 7 (0.25g) AM Part B - Treatment 1, SMT C1100, Day 7 (0.25g) PM Part B - Treatment 2, SMT C1100, Day 7 (0.5g) AM Part B - Treatment 2, SMT C1100, Day 7 (0.5g) PM Part B - Treatment 3, SMT C1100, Day 7 (1.0g) AM Part B - Treatment 3, SMT C1100, Day 7 (1.0g) PM Part B - Treatment 1, DHD I, Day 1 (0.25g) AM Part B - Treatment 1, DHD I, Day 1 (0.25g) PM Part B - Treatment 2, DHD I, Day 1 (0.5g) AM Part B - Treatment 2, DHD I, Day 1 (0.5g) PM Part B - Treatment 3, DHD I, Day 1 (1.0g) AM Part B - Treatment 3, DHD I, Day 1 (1.0g) PM Part B - Treatment 1, DHD I, Day 7 (0.25g) AM Part B - Treatment 1, DHD I, Day 7 (0.25g) PM Part B - Treatment 2, DHD I, Day 7 (0.5g) AM Part B - Treatment 2, DHD I, Day 7 (0.5g) PM Part B - Treatment 3, DHD I, Day 7 (1.0g) AM Part B - Treatment 3, DHD I, Day 7 (1.0g) PM Part B - Treatment 1, DHD III, Day 1 (0.25g) AM Part B - Treatment 1, DHD III, Day 1 (0.25g) PM Part B - Treatment 2, DHD III, Day 1 (0.5g) AM Part B - Treatment 2, DHD III, Day 1 (0.5g) PM Part B - Treatment 3, DHD III, Day 1 (1.0g) AM Part B - Treatment 3, DHD III, Day 1 (1.0g) PM Part B - Treatment 1, DHD III, Day 7 (0.25g) AM Part B - Treatment 1, DHD III, Day 7 (0.25g) PM Part B - Treatment 2, DHD III, Day 7 (0.5g) AM Part B - Treatment 2, DHD III, Day 7 (0.5g) PM Part B - Treatment 3, DHD III, Day 7 (1.0g) AM Part B - Treatment 3, DHD III, Day 7 (1.0g) PM
    Number of subjects
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
    Age categorical
    xx
    Units: Subjects
        In utero
        Preterm newborn infants (gestational age < 37 wks)
        Newborns (0-27 days)
        Infants and toddlers (28 days-23 months)
        Children (2-11 years)
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
        Adolescents (12-17 years)
        Adults (18-64 years)
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
        From 65-84 years
        85 years and over
        Not recorded
    Age continuous
    Units:
        
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    ±
    Gender categorical
    Units: Subjects
        Female
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
        Male
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
    8
    8
    6
    6
    6
    6
    8
    8
    6
    6
    6
    4
        Not recorded
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Part A - Cohort 1 SMT C1100 oral suspension (F5)
    Reporting group description
    SMT C1100 suspension drug product (also referred to as Formulation 5 [F5]) was supplied as a suspension for oral administration at a dosage strength of 100 mg/g of SMT C1100. On Days 1 to 3 subjects received oral doses of SMT C1100 suspension at 3 g SMT C1100 bid followed by 6 g SMT C1100 bid on Days 4 and 5. On Days 1 to 5 doses were administered immediately after a meal, except the morning dose on Day 5, which was administered after an overnight fast.

    Reporting group title
    Part A Cohort 2 SMT C1100 powder for oral suspension (F6)
    Reporting group description
    SMT C1100 powder for oral suspension (also referred to as Formulation 6 [F6]) was presented as a powder for reconstitution at a dosage strength of 250 mg/g of SMT C1100. The powder was presented in HDPE bottles and full fat (whole) milk was used as the reconstitution vehicle. On Days 1 (first day of dosing) to 3 subjects received oral doses of SMT C1100 powder for oral suspension at 2 g bid followed by 4 g bid on Days 4 and 5. On Days 1 to 5 doses were administered immediately after a meal, except the morning dose on Day 5, which was administered after an overnight fast.

    Reporting group title
    Part B SMT C1100 powder for oral suspension (F6)
    Reporting group description
    Subjects received SMT C1100 powder for oral suspension (F6) administered bid for 7 days in Treatment Period 1 (0.25 g bid), Treatment Period 2 (0.5 g bid) and Treatment Period 3 (1.0 g bid).

    Subject analysis set title
    Part A - Cohort 1, SMT C1100 , Day 1 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100 , Day 1 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 3 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 3 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 4 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 4 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 5 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 1, SMT C1100, Day 5 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 1 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 1 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F6 (3g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 3 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 3 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 4 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 4 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 5 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD I, Day 5 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 1 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 1 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 3 (3g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 3 (3g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (3g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 4 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 4 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 5 (6g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 1, DHD III, Day 5 (6g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 1 subjects were dosed with SMT C1100 F5 (6g) on Day 5 PM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 1 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 1 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 3 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 3 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 4 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 4 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 5 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 2, SMT C1100, Day 5 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 1 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 1 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 3 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 3 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 4 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 4 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 5 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD I, Day 5 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 1 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 1 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 1 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 3 (2g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 3 (2g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (2g) on Day 3 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 4 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 4 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 4 PM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 5 (4g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 AM.

    Subject analysis set title
    Part A - Cohort 2, DHD III, Day 5 (4g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part A - Cohort 2 subjects were dosed with SMT C1100 F6 (4g) on Day 5 PM.

    Subject analysis set title
    Part B - Treatment 1, SMT C1100, Day 1 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 1, SMT C1100, Day 1 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 2, SMT C1100, Day 1 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 2, SMT C1100, Day 1 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 3, SMT C1100, Day 1 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 3, SMT C1100, Day 1 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 1, SMT C1100, Day 7 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 1, SMT C1100, Day 7 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 2, SMT C1100, Day 7 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 2, SMT C1100, Day 7 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 3, SMT C1100, Day 7 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 3, SMT C1100, Day 7 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 1, DHD I, Day 1 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 1, DHD I, Day 1 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 2, DHD I, Day 1 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 2, DHD I, Day 1 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 3, DHD I, Day 1 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 3, DHD I, Day 1 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 1, DHD I, Day 7 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 1, DHD I, Day 7 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 2, DHD I, Day 7 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 2, DHD I, Day 7 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 3, DHD I, Day 7 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 3, DHD I, Day 7 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 1, DHD III, Day 1 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 1, DHD III, Day 1 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 2, DHD III, Day 1 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 2, DHD III, Day 1 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 3, DHD III, Day 1 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 AM.

    Subject analysis set title
    Part B - Treatment 3, DHD III, Day 1 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 1 PM.

    Subject analysis set title
    Part B - Treatment 1, DHD III, Day 7 (0.25g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 1, DHD III, Day 7 (0.25g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.25g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 2, DHD III, Day 7 (0.5g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 2, DHD III, Day 7 (0.5g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (0.5g) on Day 7 PM.

    Subject analysis set title
    Part B - Treatment 3, DHD III, Day 7 (1.0g) AM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 AM.

    Subject analysis set title
    Part B - Treatment 3, DHD III, Day 7 (1.0g) PM
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Part B - Subjects were dosed with SMT C1100 F6 (1.0g) on Day 7 PM.

    Primary: AUC 0-tau (Part A: F5 - SMT C1100; DHD I; DHD III)

    Close Top of page
    End point title
    AUC 0-tau (Part A: F5 - SMT C1100; DHD I; DHD III) [1]
    End point description
    End point type
    Primary
    End point timeframe
    Area under the plasma concentration versus time curve over a dosing interval.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Descriptive statistical analyses for the PK data are reported here.
    End point values
    Part A - Cohort 1, SMT C1100 , Day 1 (3g) AM Part A - Cohort 1, SMT C1100 , Day 1 (3g) PM Part A - Cohort 1, SMT C1100, Day 3 (3g) AM Part A - Cohort 1, SMT C1100, Day 3 (3g) PM Part A - Cohort 1, SMT C1100, Day 4 (6g) AM Part A - Cohort 1, SMT C1100, Day 4 (6g) PM Part A - Cohort 1, SMT C1100, Day 5 (6g) AM Part A - Cohort 1, SMT C1100, Day 5 (6g) PM Part A - Cohort 1, DHD I, Day 1 (3g) AM Part A - Cohort 1, DHD I, Day 1 (3g) PM Part A - Cohort 1, DHD I, Day 3 (3g) AM Part A - Cohort 1, DHD I, Day 3 (3g) PM Part A - Cohort 1, DHD I, Day 4 (6g) AM Part A - Cohort 1, DHD I, Day 4 (6g) PM Part A - Cohort 1, DHD I, Day 5 (6g) AM Part A - Cohort 1, DHD I, Day 5 (6g) PM Part A - Cohort 1, DHD III, Day 1 (3g) AM Part A - Cohort 1, DHD III, Day 1 (3g) PM Part A - Cohort 1, DHD III, Day 3 (3g) AM Part A - Cohort 1, DHD III, Day 3 (3g) PM Part A - Cohort 1, DHD III, Day 4 (6g) AM Part A - Cohort 1, DHD III, Day 4 (6g) PM Part A - Cohort 1, DHD III, Day 5 (6g) AM Part A - Cohort 1, DHD III, Day 5 (6g) PM Part A - Cohort 2, SMT C1100, Day 1 (2g) AM Part A - Cohort 2, SMT C1100, Day 1 (2g) PM Part A - Cohort 2, SMT C1100, Day 3 (2g) AM Part A - Cohort 2, SMT C1100, Day 3 (2g) PM Part A - Cohort 2, SMT C1100, Day 4 (4g) AM Part A - Cohort 2, SMT C1100, Day 4 (4g) PM Part A - Cohort 2, SMT C1100, Day 5 (4g) AM Part A - Cohort 2, SMT C1100, Day 5 (4g) PM Part A - Cohort 2, DHD I, Day 1 (2g) AM Part A - Cohort 2, DHD I, Day 1 (2g) PM Part A - Cohort 2, DHD I, Day 3 (2g) AM Part A - Cohort 2, DHD I, Day 3 (2g) PM Part A - Cohort 2, DHD I, Day 4 (4g) AM Part A - Cohort 2, DHD I, Day 4 (4g) PM Part A - Cohort 2, DHD I, Day 5 (4g) AM Part A - Cohort 2, DHD I, Day 5 (4g) PM Part A - Cohort 2, DHD III, Day 1 (2g) AM Part A - Cohort 2, DHD III, Day 1 (2g) PM Part A - Cohort 2, DHD III, Day 3 (2g) AM Part A - Cohort 2, DHD III, Day 3 (2g) PM Part A - Cohort 2, DHD III, Day 4 (4g) AM Part A - Cohort 2, DHD III, Day 4 (4g) PM Part A - Cohort 2, DHD III, Day 5 (4g) AM Part A - Cohort 2, DHD III, Day 5 (4g) PM
    Number of subjects analysed
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    Units: ng.h/ml
        geometric mean (geometric coefficient of variation)
    2048 ± 73.7
    2376 ± 92
    2066 ± 85.5
    2681 ± 109.4
    2646 ± 121.9
    3436 ± 113.8
    1850 ± 133.1
    2844 ± 105.4
    6510 ± 15.5
    9093 ± 29
    7796 ± 12.9
    9640 ± 16
    9915 ± 21
    12340 ± 19.5
    7544 ± 23.7
    11190 ± 12.9
    14790 ± 22.7
    22180 ± 26.7
    23610 ± 25.3
    21160 ± 19.9
    29210 ± 23.6
    28930 ± 18.1
    23680 ± 25.7
    25550 ± 21.6
    2268 ± 89.9
    3281 ± 84.6
    3784 ± 132.2
    3870 ± 97.6
    7823 ± 73.6
    7428 ± 79.4
    11010 ± 92
    10890 ± 104
    8784 ± 17.2
    10740 ± 21.3
    11670 ± 21.5
    12320 ± 19.7
    15420 ± 24
    15970 ± 25.9
    17030 ± 24.3
    16760 ± 16.2
    21210 ± 24.4
    29290 ± 36.2
    41750 ± 27.4
    40730 ± 31.1
    46430 ± 24.8
    48740 ± 32.2
    58160 ± 24.6
    53870 ± 21.5
    No statistical analyses for this end point

    Primary: AUC 0-24 (Part B - F6; SMT C1100)

    Close Top of page
    End point title
    AUC 0-24 (Part B - F6; SMT C1100) [2]
    End point description
    End point type
    Primary
    End point timeframe
    Area under the plasma concentration versus time curve from time zero to 24 hours.
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only exploratory statistical analyses done for this point.
    End point values
    Part B - Treatment 1, SMT C1100, Day 1 (0.25g) AM Part B - Treatment 2, SMT C1100, Day 1 (0.5g) AM Part B - Treatment 3, SMT C1100, Day 1 (1.0g) AM Part B - Treatment 1, SMT C1100, Day 7 (0.25g) AM Part B - Treatment 2, SMT C1100, Day 7 (0.5g) AM Part B - Treatment 3, SMT C1100, Day 7 (1.0g) AM Part B - Treatment 1, DHD I, Day 1 (0.25g) AM Part B - Treatment 2, DHD I, Day 1 (0.5g) AM Part B - Treatment 3, DHD I, Day 1 (1.0g) AM Part B - Treatment 1, DHD I, Day 7 (0.25g) AM Part B - Treatment 2, DHD I, Day 7 (0.5g) AM Part B - Treatment 3, DHD I, Day 7 (1.0g) AM Part B - Treatment 1, DHD III, Day 1 (0.25g) AM Part B - Treatment 2, DHD III, Day 1 (0.5g) AM Part B - Treatment 3, DHD III, Day 1 (1.0g) AM Part B - Treatment 1, DHD III, Day 7 (0.25g) AM Part B - Treatment 2, DHD III, Day 7 (0.5g) AM Part B - Treatment 3, DHD III, Day 7 (1.0g) AM
    Number of subjects analysed
    7
    5
    5
    7
    5
    4
    7
    5
    5
    7
    5
    4
    7
    5
    5
    7
    5
    4
    Units: ng.h/ml
        geometric mean (geometric coefficient of variation)
    625.1 ± 26
    1258 ± 76.7
    2601 ± 66.2
    528.6 ± 25.7
    1015 ± 30.5
    3855 ± 42.9
    8289 ± 33.9
    12110 ± 51.3
    24810 ± 28.6
    7483 ± 21.9
    11720 ± 33
    28240 ± 28.5
    20130 ± 37.4
    31710 ± 36.3
    60970 ± 29.9
    23800 ± 36.2
    34190 ± 29.7
    92850 ± 12.1
    No statistical analyses for this end point

    Primary: Cmax (Parts A & B - SMT C100; DHD I; DHD III)

    Close Top of page
    End point title
    Cmax (Parts A & B - SMT C100; DHD I; DHD III) [3]
    End point description
    End point type
    Primary
    End point timeframe
    Maximum observed concentration.
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Descriptive statistical analyses for the PK data are reported here.
    End point values
    Part A - Cohort 1, SMT C1100 , Day 1 (3g) AM Part A - Cohort 1, SMT C1100 , Day 1 (3g) PM Part A - Cohort 1, SMT C1100, Day 3 (3g) AM Part A - Cohort 1, SMT C1100, Day 3 (3g) PM Part A - Cohort 1, SMT C1100, Day 4 (6g) AM Part A - Cohort 1, SMT C1100, Day 4 (6g) PM Part A - Cohort 1, SMT C1100, Day 5 (6g) AM Part A - Cohort 1, SMT C1100, Day 5 (6g) PM Part A - Cohort 1, DHD I, Day 1 (3g) AM Part A - Cohort 1, DHD I, Day 1 (3g) PM Part A - Cohort 1, DHD I, Day 3 (3g) AM Part A - Cohort 1, DHD I, Day 3 (3g) PM Part A - Cohort 1, DHD I, Day 4 (6g) AM Part A - Cohort 1, DHD I, Day 4 (6g) PM Part A - Cohort 1, DHD I, Day 5 (6g) AM Part A - Cohort 1, DHD I, Day 5 (6g) PM Part A - Cohort 1, DHD III, Day 1 (3g) AM Part A - Cohort 1, DHD III, Day 1 (3g) PM Part A - Cohort 1, DHD III, Day 3 (3g) AM Part A - Cohort 1, DHD III, Day 3 (3g) PM Part A - Cohort 1, DHD III, Day 4 (6g) AM Part A - Cohort 1, DHD III, Day 4 (6g) PM Part A - Cohort 1, DHD III, Day 5 (6g) AM Part A - Cohort 1, DHD III, Day 5 (6g) PM Part A - Cohort 2, SMT C1100, Day 1 (2g) AM Part A - Cohort 2, SMT C1100, Day 1 (2g) PM Part A - Cohort 2, SMT C1100, Day 3 (2g) AM Part A - Cohort 2, SMT C1100, Day 3 (2g) PM Part A - Cohort 2, SMT C1100, Day 4 (4g) AM Part A - Cohort 2, SMT C1100, Day 4 (4g) PM Part A - Cohort 2, SMT C1100, Day 5 (4g) AM Part A - Cohort 2, SMT C1100, Day 5 (4g) PM Part A - Cohort 2, DHD I, Day 1 (2g) AM Part A - Cohort 2, DHD I, Day 1 (2g) PM Part A - Cohort 2, DHD I, Day 3 (2g) AM Part A - Cohort 2, DHD I, Day 3 (2g) PM Part A - Cohort 2, DHD I, Day 4 (4g) AM Part A - Cohort 2, DHD I, Day 4 (4g) PM Part A - Cohort 2, DHD I, Day 5 (4g) AM Part A - Cohort 2, DHD I, Day 5 (4g) PM Part A - Cohort 2, DHD III, Day 1 (2g) AM Part A - Cohort 2, DHD III, Day 1 (2g) PM Part A - Cohort 2, DHD III, Day 3 (2g) AM Part A - Cohort 2, DHD III, Day 3 (2g) PM Part A - Cohort 2, DHD III, Day 4 (4g) AM Part A - Cohort 2, DHD III, Day 4 (4g) PM Part A - Cohort 2, DHD III, Day 5 (4g) AM Part A - Cohort 2, DHD III, Day 5 (4g) PM Part B - Treatment 1, SMT C1100, Day 1 (0.25g) AM Part B - Treatment 1, SMT C1100, Day 1 (0.25g) PM Part B - Treatment 2, SMT C1100, Day 1 (0.5g) AM Part B - Treatment 2, SMT C1100, Day 1 (0.5g) PM Part B - Treatment 3, SMT C1100, Day 1 (1.0g) AM Part B - Treatment 3, SMT C1100, Day 1 (1.0g) PM Part B - Treatment 1, SMT C1100, Day 7 (0.25g) AM Part B - Treatment 1, SMT C1100, Day 7 (0.25g) PM Part B - Treatment 2, SMT C1100, Day 7 (0.5g) AM Part B - Treatment 2, SMT C1100, Day 7 (0.5g) PM Part B - Treatment 3, SMT C1100, Day 7 (1.0g) AM Part B - Treatment 3, SMT C1100, Day 7 (1.0g) PM Part B - Treatment 1, DHD I, Day 1 (0.25g) AM Part B - Treatment 1, DHD I, Day 1 (0.25g) PM Part B - Treatment 2, DHD I, Day 1 (0.5g) AM Part B - Treatment 2, DHD I, Day 1 (0.5g) PM Part B - Treatment 3, DHD I, Day 1 (1.0g) AM Part B - Treatment 3, DHD I, Day 1 (1.0g) PM Part B - Treatment 1, DHD I, Day 7 (0.25g) AM Part B - Treatment 1, DHD I, Day 7 (0.25g) PM Part B - Treatment 2, DHD I, Day 7 (0.5g) AM Part B - Treatment 2, DHD I, Day 7 (0.5g) PM Part B - Treatment 3, DHD I, Day 7 (1.0g) AM Part B - Treatment 3, DHD I, Day 7 (1.0g) PM Part B - Treatment 1, DHD III, Day 1 (0.25g) AM Part B - Treatment 1, DHD III, Day 1 (0.25g) PM Part B - Treatment 2, DHD III, Day 1 (0.5g) AM Part B - Treatment 2, DHD III, Day 1 (0.5g) PM Part B - Treatment 3, DHD III, Day 1 (1.0g) AM Part B - Treatment 3, DHD III, Day 1 (1.0g) PM Part B - Treatment 1, DHD III, Day 7 (0.25g) AM Part B - Treatment 1, DHD III, Day 7 (0.25g) PM Part B - Treatment 2, DHD III, Day 7 (0.5g) AM Part B - Treatment 2, DHD III, Day 7 (0.5g) PM Part B - Treatment 3, DHD III, Day 7 (1.0g) AM Part B - Treatment 3, DHD III, Day 7 (1.0g) PM
    Number of subjects analysed
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    8
    8
    8
    8
    8
    8
    7
    7
    7
    7
    5
    5
    5
    5
    7
    7
    5
    5
    5
    4
    7
    7
    5
    5
    5
    5
    7
    7
    5
    5
    5
    4
    7
    7
    5
    5
    5
    5
    7
    7
    5
    5
    5
    4
    Units: ng/ml
        geometric mean (geometric coefficient of variation)
    397.4 ± 81.3
    312.3 ± 98.1
    346.6 ± 87.7
    389.2 ± 100.5
    489.1 ± 117.3
    445.3 ± 114.8
    345.2 ± 134.8
    371.5 ± 109.6
    1053 ± 17.2
    1093 ± 27.5
    1174 ± 18.2
    1251 ± 18.7
    1556 ± 21.6
    1429 ± 23.6
    1245 ± 19.1
    1262 ± 12.7
    1923 ± 24.3
    2590 ± 25.9
    3037 ± 19.3
    2645 ± 19.5
    3641 ± 25.8
    3066 ± 15.2
    3054 ± 21.5
    2624 ± 18.9
    459 ± 96.4
    714.6 ± 69.1
    683.6 ± 120.6
    746.1 ± 81.7
    1563 ± 55.6
    1556 ± 63.8
    2125 ± 71.1
    2279 ± 104.7
    1376 ± 27.2
    1400 ± 27.3
    1654 ± 19.6
    1471 ± 10.4
    2050 ± 22.3
    1804 ± 16.8
    2443 ± 21.7
    1947 ± 15
    2766 ± 23
    3602 ± 34
    4485 ± 24.7
    4193 ± 29.7
    5064 ± 26.4
    5129 ± 27.2
    6344 ± 27
    5741 ± 22.1
    93.16 ± 28.2
    43.74 ± 51.8
    176.6 ± 108.1
    113.6 ± 201.2
    265.5 ± 102.4
    212.9 ± 86.6
    49.64 ± 43.1
    39.03 ± 52.6
    114.6 ± 67.3
    78.98 ± 55
    282.8 ± 49.1
    415.6 ± 67.6
    726.2 ± 20.1
    596.8 ± 29.8
    1175 ± 43.9
    831.9 ± 84.8
    1711 ± 37
    1555 ± 26
    606.3 ± 36.3
    585.3 ± 16.9
    1087 ± 44.7
    820.3 ± 23.5
    1799 ± 48.6
    2038 ± 24.8
    1625 ± 29.2
    1170 ± 29.8
    2439 ± 33.5
    1971 ± 59.2
    3647 ± 22.7
    3641 ± 28.1
    1859 ± 25.5
    1501 ± 34.6
    2626 ± 41.6
    2039 ± 20.2
    5012 ± 33.9
    5088 ± 8
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Duration of the study.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    18
    Reporting groups
    Reporting group title
    Part A Cohort 1 SMT C1100 oral suspension
    Reporting group description
    On Days 1 to 3 subjects received oral doses of SMT C1100 suspension at 3 g SMT C1100 bid followed by 6 g SMT C1100 bid on Days 4 and 5. On Days 1 to 5 doses were administered immediately after a meal, except the morning dose on Day 5, which was administered after an overnight fast.

    Reporting group title
    Part A Cohort 2 SMT C1100 powder for oral suspension
    Reporting group description
    On Days 1 to 3 subjects received oral doses of SMT C1100 powder for oral suspension at 2 g SMT C1100 bid followed by 4 g SMT C1100 bid on Days 4 and 5. On Days 1 to 5 doses were administered immediately after a meal, except the morning dose on Day 5, which was administered after an overnight fast.

    Reporting group title
    Part B SMT C1100 powder for oral suspension-0.25g bid
    Reporting group description
    Subjects received SMT C1100 powder for oral suspension (F6) administered 0.25 g bid for 7 days in Treatment Period 1.

    Reporting group title
    Part B SMT C1100 powder for oral suspension-0.5g bid
    Reporting group description
    Subjects received SMT C1100 powder for oral suspension (F6) administered 0.5 g bid for 7 days in Treatment Period 2.

    Reporting group title
    Part B SMT C1100 powder for oral suspension-1.0g bid
    Reporting group description
    Subjects received SMT C1100 powder for oral suspension (F6) administered 1.0 g bid for 7 days in Treatment Period 3.

    Serious adverse events
    Part A Cohort 1 SMT C1100 oral suspension Part A Cohort 2 SMT C1100 powder for oral suspension Part B SMT C1100 powder for oral suspension-0.25g bid Part B SMT C1100 powder for oral suspension-0.5g bid Part B SMT C1100 powder for oral suspension-1.0g bid
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    Investigations
    Liver function test abnormal
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Part A Cohort 1 SMT C1100 oral suspension Part A Cohort 2 SMT C1100 powder for oral suspension Part B SMT C1100 powder for oral suspension-0.25g bid Part B SMT C1100 powder for oral suspension-0.5g bid Part B SMT C1100 powder for oral suspension-1.0g bid
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    8 / 8 (100.00%)
    8 / 8 (100.00%)
    5 / 8 (62.50%)
    4 / 6 (66.67%)
    2 / 6 (33.33%)
    Injury, poisoning and procedural complications
    Road traffic accident
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    1 / 8 (12.50%)
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    2
    0
    0
    0
    Presyncope
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    General disorders and administration site conditions
    Catheter site related reaction
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    Fatigue
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    Non-cardiac chest pain
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    Medical device site reaction
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Pyrexia
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Gastrointestinal disorders
    Change of bowel habit
         subjects affected / exposed
    0 / 8 (0.00%)
    5 / 8 (62.50%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    5
    0
    0
    0
    Faeces discoloured
         subjects affected / exposed
    8 / 8 (100.00%)
    4 / 8 (50.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    8
    4
    0
    0
    0
    Abdominal discomfort
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    Faeces pale
         subjects affected / exposed
    0 / 8 (0.00%)
    2 / 8 (25.00%)
    0 / 8 (0.00%)
    2 / 6 (33.33%)
    0 / 6 (0.00%)
         occurrences all number
    0
    2
    0
    2
    0
    Abdominal pain
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    1
    0
    1
    Diarrhoea
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    2 / 6 (33.33%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    1
    2
    1
    Dyspepsia
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Nausea
         subjects affected / exposed
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    1
    1
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
         occurrences all number
    0
    0
    1
    1
    0
    Haemorrhoids
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 6 (16.67%)
    0 / 6 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Vomiting
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Dry throat
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    Renal and urinary disorders
    Pollakiuria
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Psychiatric disorders
    Aggression
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    0
    0
    0
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    Myalgia
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    Pain in extremity
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    0
    0
    0
    1
    Infections and infestations
    Rhinitis
         subjects affected / exposed
    1 / 8 (12.50%)
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 8 (0.00%)
    0 / 8 (0.00%)
    1 / 8 (12.50%)
    0 / 6 (0.00%)
    0 / 6 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Nil
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 28 09:43:33 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA